Ocular HSV: A leading cause of blindness1

Annually in the United States, there are:

~20,000 New Cases of Ocular HSV

~20,000

new cases
of ocular HSV

>28,000 Cases of Recurrence

>28,000

cases
of recurrence

~500,000 People with HSV‐Related Ocular Disease

~500,000

people WITH
HSV-related
ocular disease

INDICATION

ZIRGAN (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated
for the treatment of acute herpetic keratitis (dendritic ulcers).

Accessing ZIRGAN

See if your patients are covered with Bausch + Lomb’s formulary tool.

Check our formulary tool
How ZIRGAN works

Learn more about how ZIRGAN works in the eye.

See ZIRGAN in action
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

References: 1. Wang JC, Ritterband DC. Herpes simplex virus (HSV) keratitis. Medscape Website. https://emedicine.medscape.com/article/1194268-overview#a6. Updated November 3, 2017. Accessed August 16, 2018.

 

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below:

Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.